Triflusal versus aspirin for the prevention of stroke

Progress in Neurotherapeutics and Neuropsychopharmacology

Volumn 3, Issue 1, 2008, Pages 13-33

  Culebras, Antonio ^a   Borja, Javier ^b   García Rafanell, Julián ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b J Uriach y Compania   (Spain)

Author keywords

Antiplatelet agent; Aspirin; Stroke; Transient ischemic attack; Triflusal

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPYRIDAMOLE; DRUG METABOLITE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; THROMBOXANE; TICLOPIDINE; TRIFLUSAL; WARFARIN;

ACUTE HEART INFARCTION; ALZHEIMER DISEASE; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GRAFT OCCLUSION; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HEMATOMA; HEMATURIA; HUMAN; INTRAOCULAR HEMORRHAGE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; PEPTIC ULCER; PILOT STUDY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RESPIRATORY TRACT HEMORRHAGE; SINGLE DRUG DOSE; SKIN MANIFESTATION; SKIN TOXICITY; STOMACH ULCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; UPPER GASTROINTESTINAL BLEEDING;

EID: 39449109435     PISSN: 17482321     EISSN: 1748233X     Source Type: Journal    
DOI: 10.1017/S1748232107000092     Document Type: Article

References (42)

1. Acarin, L., González, B., & Castellano, B. (2002). Decrease of proinflammatory molecules correlates with neuroprotective effect of the fluorinated salicylate triflusal after postnatal excitotoxic, damage. Stroke, 33, 2499-2505.
2. Albers, G.W., Amarenco, P., Easton, J.D., & Sacco, R.L. (2004). Antithrombotic and thrombolytic therapy for ischemic stroke. The seventh ACCP Conference on antithrombotic and thrombolytic: Therapy. Chest 126, 483S-512S.
3. Albors, M., de Castellarnau, C., Vila, L., et al. (1987). Inhibition of thromboxane production and platelet function by triflusal in healthy volunteers. Revista de Farmacología Clínica y Experimental 4, 11-16.
4. Antiplatelet Trialist's Collaboration (1994). Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 308, 81-106.
5. Antithrombotic Trialists' Collaboration (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal, 324, 71-86.
6. Aramendi, J.I., Mestres, C.A., Martinez-León, J., et al. (2005). Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic: Valve replacement (trac): prospective, randomized, co-operative trial. European Journal of Cardio-Thoracic Surgery, 27, 854-860.
7. Bayón, Y., Alonso, A., & Sánchez Crespo, M. (1999). 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic: Acid, are potent inhibitors of nuclear factor κ B activation. British Journal of Pharmacology, 126, 1359-1366.
8. CAPRIE Steering Committee (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348, 1329-1339.
9. Costa, J., Ferro, J.M., Matias-Guiu, J., Alvarez-Sabín, J., & Torres, F. (2005). Triflusal for preventing serious vascular events in people at high risk. The Cochrane Database of Systematic Reviews 2005, 3, Art. N.: CD004296.pub2. DOI:10.1002/ 14651858.CD004296.pub.2.
10. Cruz-Fernández, J.M. (2001). Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxigenase inhibitors. European Heart Journal, 3(Suppl. 1), 123-130.
11. Cruz-Fernández, J.M., Lopez-Bescós, L., Garcia-Dorado, D., et al. (2000). Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. European Heart Journal 21, 457-465.
12. Culebras, A., Rotta-Escalante R., Dominguez, R., et al. (2004). Triflusal vs aspirin for prevention of cerebral infarction. Neurology, 62, 1073-1080.
13. Dela Cruz, G., Sorio, F., Pérez, I., et al. (2002). Estudio de seguridad del triflusal, en pacientes asmáricos con intolerancia a aspirina y/o AINES. Revista do medicina de la Universidad de Navarra, 14, 5-46.
14. De La Cruz, J.P., Pavía, J., García-Arnes, J., et al. (1998). Effects of trifusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients. European Journal of Haematology, 40, 232-236.
15. De La Cruz, J.P., Pavía, J., Bellido, I., et al. (1995a). Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers. European Journal of Clinical Pharmacology, 47, 497-502.
16. De La Cruz, J.P., Villalobos, M.A., García, P.J., et al. (1995b). Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers. European Journal of Clinical Pharmacology, 47, 497-502.
17. Diener, H.C., Cunha, L., Forbes, C., Sivenius, J., Smets, P., & Lowenthal, A. (1996). European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the Neurological Sciences, 143, 1-13.
18. Domínguez, M.J., Vacas, M., Sáez, Y., et al. (1985). Effects of triflusal in patients with prosthetic valves. Clinical Therapeutics, 7, 357-360.
19. Edvarson, N., Juul-Moller, S., Omblus, R., & Pehersson, K. (2003). Effect of low dose warfarin and aspirin on stroke versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. Journal of Internal Medicine, 254, 95-101.
20. Ferrari, E., Reboldi, G., Marenco, P., et al. (1996). Pharmacokinetic study of triflusal in elderly subjects after single and repeated oral administration. American Journal of Therapeutics, 3, 630-636.
21. García-Rafanell, J., Ramis, J., Gómez, L., et al. (1986). Eflect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Archives Internationales de Pharmacodynamic et de Therapie, 284, 155-165.
22. Goldstein, L.B., Adams, R., Becker, K., et al. (2001). Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke, 32, 280-299.
23. Guiteras, P., Altimiras, J., Arís, A., et al. (1989). Prevention of aortocoronary vein-graft attrition with low-dose-aspirin and triflusal, both associated with dipyridamole: A randomized, double-blind, placebo-controlled trial. European Heart-Journal, 10, 159-167.
24. Gullov, A.L., Koefoed., B.G., Petersen, P., et al. (1998). Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: second copenhagen atrial fibrillation, aspirin and anticoagulation study. Archives of Internal Medicine, 158, 1513-1521.
25. Heye, N., Campos, A., Kannuki, S., et al. (1991). Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain ischemia. Experimental Pathology, 41, 31-36.
26. Ibáñez, L., Vidal, X., Vendrell, L., Moretti, U., & Laporte, J.R. (2006). Upper gastrointestinal bleeding associated with antiplatelet drugs. Alimentary Pharmacology & Therapeutics, 23, 235-242.
27. Lanas, A., Serrano, P., Bajador, E., Fuentes, J., & Sainz, R. (2003). Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. European Journal of Gastroenterology and Hepatology, 15, 173-178.
28. Matías-Guíu, J., Ferro, J.M., Alvarez-Sabín, J., et al. (2003). Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP study: a randomized, double-blind, multicenter trial. Stroke, 34, 840-848.
29. Matías-Guíu, J., Alvarez-Sabín, J., & Codina, A. (1997). Estudio comparativo del efecto del ácido acetilsalicilico en dosis bajas y el triflusal en la prevención de eventos cardiovasculares en adultos jóvenes con enfermedad cerebrovascular isquémica. Revista de Neurologia, 25, 1669-1672.
30. Mc Neely, W., & Goa, K.L. (1998). Triflusal. Drugs, 55, 823-833.'
31. Patrono, C., Coller, B., Dalen, J.E., et al. (2001). Platelet-active drugs: The relationship among dose, effectiveness, and side effects. Chest, 119, 39S-63S.
32. Pérez-Gómez, F., Alegria, E., Berjón, J., et al. for the NASPEAF Investigators (2004). Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation. Journal of the American College of Cardiology, 44, 1557-1566.
33. Plaza, L., López-Bescós, L., Martin-Jadraque, L., et al. (1993). Protective effect of triflusal against acute myocardial infarction in patients with instable angina: Results of a Spanish multicenter trial. Cardiology, 82, 388-398.
34. Ramis, J., Mis, R., Forn, J., et al. (1991). Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. European Journal of Drug Metabolism and Pharmacokinetics, 16, 269-273.
35. Ramis, J., Torrent, J., Mis, R., et al. (1990). Pharmacokinetics of triflusal after single and repeated doses in man. International Journal of Clinical Pharmacolog Therapy, & Toxicology, 28, 344-349.
36. Sánchez de Miguel, L., Montón, M., Arriero, M.M., et al. (2000). Effect of triflusal on human platelet aggregation and secretion: Role of nitric oxide. Revista Espanola DeCardiologia, 53, 205-211.
37. Smirne, S., Ferini.-Strambi, L., Cucinotta, D. (1994). Triflusal and prevention of cerebrovascular attacks: A double-blind clinical study versus ASA. Journal of Neurology, 241 (Suppl. 1), S130.
38. Stroke Prevention in Atrial Fibrillation III Investigators (1996). Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348, 633-638.
39. Valle, M., Barbanoj, M.J., Donner, A., et al. (2005). Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. European Journal of Clinical Pharmacology, 61, 103-111.
40. White, H.D., Gersh, B.J., & Opie, L.H. (2001). Antithrombotic agents: Platelet inhibitors, anticoagulants and fibrinolytics. In: Opie, L.H., & Gersh, B.J. (eds.), Drugs for the Heart (5th ed.). Philadelphia: W.B. Saunders Company, pp. 273-322.
41. Whitehead, S., Cheng, G., Hachinaki, V., & Cechetto, D.F. (2005), Interaction between a rat model of cerebral ischemia and β-amiloid toxicity. II. Effects of triflusal. Stroke, 36, 1782-1789.
42. Weisman, S.M., & Graham, D.Y. (2002). Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Archives of Internal Medicine, 162, 2197-2202.